kicked off on Monday, with Aclaris Therapeutics Inc (NASDAQ: ACRS) stock price up 6.25% from the previous day of trading, before settling in for the closing price of $1.60. ACRS’s price has ranged from $0.95 to $5.17 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
A company in the Healthcare sector has jumped its sales by 72.53% annually for the last half of the decade. Meanwhile, its annual earnings per share averaged 64.91%. With a float of $91.37 million, this company’s outstanding shares have now reached $107.85 million.
In an organization with 64 employees, it is important to assess its efficiency. In terms of profitability, gross margin is 17.43%, operating margin of -728.22%, and the pretax margin is -705.44%.
Aclaris Therapeutics Inc (ACRS) Insider and Institutional Ownership
As we move forward, let’s examine how large-scale investors are investing in this stock of the Diagnostics & Research Industry. The insider ownership of Aclaris Therapeutics Inc is 15.34%, while institutional ownership is 68.58%. The most recent insider transaction that took place on Nov 19 ’24, was worth 1,499,998. In this transaction Director of this company bought 666,666 shares at a rate of $2.25, taking the stock ownership to the 710,030 shares. Before that another transaction happened on Aug 05 ’24, when Company’s 10% Owner bought 206,025 for $1.24, making the entire transaction worth $256,357. This insider now owns 14,250,000 shares in total.
Aclaris Therapeutics Inc (ACRS) Latest Financial update
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.15 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 64.91% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 19.51% during the next five years compared to 15.24% growth over the previous five years of trading.
Aclaris Therapeutics Inc (NASDAQ: ACRS) Trading Performance Indicators
Here are Aclaris Therapeutics Inc’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 3.99. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 9.80.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.51, a number that is poised to hit -0.13 in the next quarter and is forecasted to reach -0.74 in one year’s time.
Technical Analysis of Aclaris Therapeutics Inc (ACRS)
Let’s dig in a bit further. During the last 5-days, its volume was 1.62 million. That was better than the volume of 0.93 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 51.24%. Additionally, its Average True Range was 0.13.
During the past 100 days, Aclaris Therapeutics Inc’s (ACRS) raw stochastic average was set at 5.58%, which indicates a significant decrease from 38.50% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 54.93% in the past 14 days, which was lower than the 119.91% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $2.1476, while its 200-day Moving Average is $1.8846. However, in the short run, Aclaris Therapeutics Inc’s stock first resistance to watch stands at $1.7733. Second resistance stands at $1.8467. The third major resistance level sits at $1.9383. If the price goes on to break the first support level at $1.6083, it is likely to go to the next support level at $1.5167. The third support level lies at $1.4433 if the price breaches the second support level.
Aclaris Therapeutics Inc (NASDAQ: ACRS) Key Stats
With a market capitalization of 183.46 million, the company has a total of 107,919K Shares Outstanding. Currently, annual sales are 18,720 K while annual income is -132,070 K. The company’s previous quarter sales were 9,210 K while its latest quarter income was -96,550 K.
